These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 39058509)
1. Naloxone Availability and Cost After Transition to an Over-the-Counter Product. Marley GT; Annis IE; Egan KL; Delamater P; Carpenter DM JAMA Health Forum; 2024 Jul; 5(7):e241920. PubMed ID: 39058509 [TBL] [Abstract][Full Text] [Related]
2. Naloxone Accessibility by Standing Order in North Carolina Community Pharmacies. Marley G; Annis IE; Ostrach B; Egan K; Delamater PL; Bell R; Dasgupta N; Carpenter DM J Am Pharm Assoc (2003); 2024; 64(3):102021. PubMed ID: 38307248 [TBL] [Abstract][Full Text] [Related]
3. Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017. Guadamuz JS; Alexander GC; Chaudhri T; Trotzky-Sirr R; Qato DM JAMA Netw Open; 2019 Jun; 2(6):e195388. PubMed ID: 31173125 [TBL] [Abstract][Full Text] [Related]
4. Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies. Graves RL; Andreyeva E; Perrone J; Shofer FS; Merchant RM; Meisel ZF J Addict Med; 2019; 13(4):272-278. PubMed ID: 30585876 [TBL] [Abstract][Full Text] [Related]
5. Naloxone Availability in Retail Pharmacies and Neighborhood Inequities in Access. Egan KL; Foster SE; Knudsen AN; Lee JGL Am J Prev Med; 2020 May; 58(5):699-702. PubMed ID: 32005590 [TBL] [Abstract][Full Text] [Related]
6. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama. Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165 [TBL] [Abstract][Full Text] [Related]
7. Will converting naloxone to over-the-counter status increase pharmacy sales? Murphy SM; Morgan JR; Jeng PJ; Schackman BR Health Serv Res; 2019 Aug; 54(4):764-772. PubMed ID: 30790269 [TBL] [Abstract][Full Text] [Related]
8. Naloxone Accessibility Under the State Standing Order Across Mississippi. Gravlee E; Ramachandran S; Cafer A; Holmes E; McGregor J; Jordan T; Rosenthal M JAMA Netw Open; 2023 Jul; 6(7):e2321939. PubMed ID: 37410464 [TBL] [Abstract][Full Text] [Related]
9. Point-of-sale Naloxone: Novel Community-based Research to Identify Naloxone Availability. Olives T; Willhite LA; Lee SC; Evans DK; Jensen A; Regelman HT; McGillis ES West J Emerg Med; 2020 Aug; 21(5):1188-1194. PubMed ID: 32970574 [TBL] [Abstract][Full Text] [Related]
10. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. Stopka TJ; Donahue A; Hutcheson M; Green TC J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540 [TBL] [Abstract][Full Text] [Related]
11. Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire. Bolivar D; Hartung D; Silcox J; Bratberg J; Boggis J; Rabin M; Green TC J Am Pharm Assoc (2003); 2023; 63(1):330-335.e1. PubMed ID: 36369076 [TBL] [Abstract][Full Text] [Related]
12. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Hill LG; Loera LJ; Evoy KE; Renfro ML; Torrez SB; Zagorski CM; Perez JC; Jones SM; Reveles KR Addiction; 2021 Jun; 116(6):1505-1511. PubMed ID: 33140519 [TBL] [Abstract][Full Text] [Related]
13. Availability of Naloxone in Pharmacies and Knowledge of Pharmacy Staff Regarding Dispensing Naloxone to Younger Adolescents. Jimenez DE; Singer MR; Adesman A J Adolesc Health; 2019 Nov; 65(5):698-701. PubMed ID: 31540779 [TBL] [Abstract][Full Text] [Related]
14. Accessibility of Naloxone in Pharmacies Registered Under the Illinois Standing Order. Quincy Moore P; Ellis K; Simmer P; Waetjen M; Almirol E; Salisbury-Afshar E; Pho MT West J Emerg Med; 2024 Jul; 25(4):457-464. PubMed ID: 39028230 [TBL] [Abstract][Full Text] [Related]
15. The association between naloxone claims and proportion of independent versus chain pharmacies: A longitudinal analysis of naloxone claims in the United States. Freibott CE; Jalali A; Murphy SM; Walley AY; Linas BP; Jeng PJ; Bratberg J; Marshall BDL; Zang X; Green TC; Morgan JR J Am Pharm Assoc (2003); 2024; 64(4):102093. PubMed ID: 38604474 [TBL] [Abstract][Full Text] [Related]
16. Pharmacist dispensed naloxone: Knowledge, availability, participation and cost in selected California counties. Darracq MA; Lee J; Wilson T; Lasoff D; Armenian P Int J Drug Policy; 2019 Sep; 71():113-117. PubMed ID: 31301549 [TBL] [Abstract][Full Text] [Related]
17. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review. Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151 [TBL] [Abstract][Full Text] [Related]
19. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255 [TBL] [Abstract][Full Text] [Related]
20. Community pharmacy naloxone supply, before and after rescheduling as an over-the-counter drug: sales and prescriptions data, 2014-2018. Tse WC; Sanfilippo P; Lam T; Dietze P; Nielsen S Med J Aust; 2020 Apr; 212(7):314-320. PubMed ID: 32124984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]